Posts by: Patricia Inacio, PhD

News

A simple test of amyloid-beta protein levels in a person’s blood may offer a way to diagnose Alzheimer’s disease up to eight years before any clinical symptoms are evident, ... Read more

April 16, 2018April 17, 2018

#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients

News

An injection of IONIS-MAPTRx resulted in a 70 percent decrease in tau protein produced in the brains of non-human primates, researchers at Ionis Pharmaceuticals, the potential treatment’s maker, are ... Read more

April 13, 2018April 13, 2018

Chronic Exposure to Caffeine Worsened Symptoms in Alzheimer’s Mouse Model

News

Long-term exposure to caffeine worsens Alzheimer’s disease symptoms, a new mouse study shows. The study “Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s ... Read more

April 9, 2018April 9, 2018

Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy

News

Spanish regulators have signed off on Oryzon Genomics’ plan to conduct a Phase 2 clinical trial of its Alzheimer’s therapy ORY-2001. The ETHERAL trial, which will cover patients with mild to moderate ... Read more

April 6, 2018April 6, 2018

Increasing the Activity of Certain Type of Nerve Cell Restores Cognition, Mouse Study Shows

News

The brain works in a coordinated matter, like a tuned orchestra, scientists say. If a single instrument is out of sync, it affects the entire ensemble. In Alzheimer’s disease, damage to certain ... Read more

February 14, 2018February 14, 2018

Harmful Tau Protein Shows Up in One Brain Area, Then Spreads, Study Reports

News

The harmful tau protein associated with Alzheimer’s appears in one place in the brain, then spreads, rather than showing up in several places independently, new imaging techniques show. This ... Read more

February 7, 2018February 7, 2018

Idalopirdine Plus Cholinesterase Inhibitors Doesn’t Help Alzheimer’s Patients, Study Finds

News

Three Phase 3 clinical studies have failed to reproduce previously reported benefits of adding investigational idalopirdine to a background therapy of cholinesterase inhibitors. The three randomized trials detected no ... Read more

February 5, 2018February 5, 2018

Gut Microbiome May Have Central Role in Alzheimer’s and Like Diseases, Study Argues

News

The gut microbiome is increasingly seen as a key player in serious and chronic neurodegenerative diseases like Alzheimer’s and Parkinson’s — for reasons that are being suggested and explained, ... Read more

January 26, 2018February 26, 2018

Scientists Discover How a Therapy Both Treats Alzheimer’s and Reverses Aging

News

Salk Institute researchers have discovered how a therapy they are developing alleviates the symptoms of Alzheimer’s disease and reverses aging in mice. The compound, J147, does this by binding to ... Read more

January 11, 2018

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds

News

ProMIS Neurosciences’ Alzheimer’s therapy PMN310 attacks toxic forms of a protein linked to the disease but not normal forms, a preclinical-trial study indicates. Other therapies go after both forms of amyloid ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Blood Test for Toxic Amyloid May Detect Alzheimer’s 8 Years Before Symptoms, Study Says

#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients

Chronic Exposure to Caffeine Worsened Symptoms in Alzheimer’s Mouse Model

Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy

Increasing the Activity of Certain Type of Nerve Cell Restores Cognition, Mouse Study Shows

Harmful Tau Protein Shows Up in One Brain Area, Then Spreads, Study Reports

Idalopirdine Plus Cholinesterase Inhibitors Doesn’t Help Alzheimer’s Patients, Study Finds

Gut Microbiome May Have Central Role in Alzheimer’s and Like Diseases, Study Argues

Scientists Discover How a Therapy Both Treats Alzheimer’s and Reverses Aging

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds

Pin It on Pinterest